文献速递衰弱、肌少症与跌倒老年综合评估

用于居家真实场景衰弱监测的数字生物标志物:系统综述与荟萃分析

Digital biomarkers for real-life, home-based monitoring of frailty: a systematic review and meta-analysis.
PubMed 文献 · Age Ageing · 2025-01-01

该系统综述与荟萃分析检索五个数据库至2024年8月1日,纳入16项研究,识别出步态、活动、睡眠、心率、手部运动和房间转换等用于衰弱检测的数字生物标志物。荟萃分析显示,区分健壮与衰弱前期/衰弱参与者的合并敏感度为0.78(95%CI:0.70-0.86),特异度为0.79(95%CI:0.72-0.86)。所有纳入研究存在高或不明确的偏倚风险,结论认为数字生物标志物在居家早期预测衰弱方面有潜力,但需更大样本的纵向研究验证。

要点

  • 居家数字生物标志物涵盖步态、活动、睡眠、心率、手部运动和房间转换。
  • 区分健壮与衰弱前期/衰弱的合并敏感度0.78,特异度0.79。
  • 所有纳入研究偏倚风险为高或不明确,证据质量有限。

核心结论

  • 数字生物标志物在居家场景中对衰弱早期预测具有潜力,但作为诊断工具或预后指标的有效性仍需更大样本的纵向研究验证。

研究设计与样本

  • 系统综述与荟萃分析,检索五个数据库自建库至2024年8月1日,最终纳入16项研究,采用标准化表格提取数据,并使用QUADAS工具评估偏倚风险与适用性。

主要发现

  • 系统综述识别出步态、活动、睡眠、心率、手部运动和房间转换等与衰弱检测相关的数字生物标志物。
  • 荟萃分析显示,区分健壮与衰弱前期/衰弱参与者的合并敏感度为0.78(95%CI:0.70-0.86),合并特异度为0.79(95%CI:0.72-0.86)。
  • 所有纳入研究的偏倚风险总体评估为高或不明确。

关键数值与推荐

  • 合并敏感度0.78(95%CI:0.70-0.86),用于区分健壮与衰弱前期/衰弱参与者。
  • 合并特异度0.79(95%CI:0.72-0.86),用于区分健壮与衰弱前期/衰弱参与者。

临床怎么用

  • 在老年医学科居家场景中,可关注步态、活动、睡眠、心率、手部运动和房间转换等数字生物标志物用于衰弱早期筛查。
  • 鉴于合并敏感度与特异度均约0.78-0.79且偏倚风险较高,数字生物标志物结果应结合临床综合评估使用。

局限性

  • 所有纳入研究均存在高或不明确的偏倚风险。
  • 需要更大样本的纵向研究来验证数字生物标志物作为诊断工具或预后指标的有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Frailty, characterised by decreased physiological function and increased vulnerability to stressors, was associated with an increase in numerous adverse outcomes. Although the number of digital biomarkers for detecting frailty in older adults is increasing, there remains a lack of evidence regarding their effectiveness for early detection and follow-up in real-world, home-based settings. METHODS: Five databases were searched from inception until 1 August 2024. Standardised forms were utilised for data extraction. The Quality Assessment of Diagnostic Accuracy Studies was used to assess the risk of bias and applicability of included studies. A meta-analysis was conducted to assess the overall sensitivity and specificity for frailty detection. RESULTS: The systematic review included 16 studies, identifying digital biomarkers relevant for frailty detection, including gait, activity, sleep, heart rate, hand movements and room transition. Meta-analysis further revealed pooled sensitivity of 0.78 [95% confidence interval (CI): 0.70-0.86] and specificity of 0.79 (95% CI: 0.72-0.86) to classify robust and pre-frailty/frailty participants. The overall risk of bias indicated that all the included studies were characterised as having a high or unclear risk of bias. CONCLUSION: This study offers a thorough characterisation of digital biomarkers for detecting frailty, underscoring their potential for early prediction in home settings. These findings are instrumental in bridging the gap between evidence and practice, enabling more proactive and personalised healthcare monitoring. Further longitudinal studies involving larger sample sizes are necessary to validate the effectiveness of these digital biomarkers as diagnostic tools or prognostic indicators.

来源:Age Ageing,查看原文。版权归原作者所有。

引用

  1. Huang J, Zhou S, Xie Q, et al. Digital biomarkers for real-life, home-based monitoring of frailty: a systematic review and meta-analysis. Age Ageing. 2025. PMID: 40251836. doi:10.1093/ageing/afaf108

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。